Update Breast Cancer 2019 part 5

• Verfasst von: Welslau, Manfred [VerfasserIn]
• Verfasst von: Schütz, Florian [VerfasserIn]
• Verfasst von: Wallwiener, Markus [VerfasserIn]
• Verfasst von: Schneeweiss, Andreas [VerfasserIn]
• Titel: Update Breast Cancer 2019 part 5
• Titelzusatz: diagnostic and therapeutic challenges of new, personalised therapies in patients with advanced breast cancer
• Paralleltitel: Update Mammakarzinom 2019 Teil 5
• Paralleltitelzusatz: diagnostische und therapeutische Herausforderungen neuer personalisierter Therapien bei Patientinnen mit fortgeschrittenem Mammakarzinom
• Verf.angabe: Manfred Welslau, Andreas D. Hartkopf, Volkmar Müller, Achim Wöckel, Michael P. Lux, Wolfgang Janni, Johannes Ettl, Diana Lüftner, Erik Belleville, Florian Schütz, Peter A. Fasching, Hans-Christian Kolberg, Naiba Nabieva, Friedrich Overkamp, Florin-Andrei Taran, Sara Y. Brucker, Markus Wallwiener, Hans Tesch, Andreas Schneeweiss, Tanja N. Fehm
• Jahr: 2019
• Umfang: 10 S.
• Fussnoten: Gesehen am 05.05.2020
• Titel Quelle: Enthalten in: Geburtshilfe und Frauenheilkunde
• Ort Quelle: Stuttgart : Thieme, 1980
• Jahr Quelle: 2019
• Band/Heft Quelle: 79(2019), 10, Seite 1090-1099
• ISSN Quelle: 1438-8804
• DOI: doi:10.1055/a-1001-9952
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1697238521

Abstract

Significant advancements have been made in recent years in advanced breast cancer and nearly all of them have been in the field of targeted therapy. Pertuzumab and trastuzumab-emtansine (T-DM1) have been able to be introduced in HER2-positive breast cancer. Now other anti-HER2 therapies are being developed (e.g. margetuximab, DS-8201a, pyrotinib) which can overcome other resistance mechanisms in the HER2 signalling pathway. In the field of hormone-receptor-positive breast cancer, an mTOR inhibitor and CDK4/6 inhibitors were introduced in the past. Now the introduction of the first PI3K inhibitor is forthcoming and this inhibitor will involve genetic testing of the tumour for a mutation in the PIK3CA gene. There are also significant advancements in triple-negative breast cancer: By combining chemotherapy and immunotherapy, an advantage for overall survival was able to be demonstrated in a subgroup (immune cells PD-L1-positive). The PARP inhibitor therapy for HER2-negative patients with a germ line mutation in BRCA1 or BRCA2 was also associated with an improved overall survival in a subgroup. These promising new study results are summarised in this review.